JPH0250086B2 - - Google Patents
Info
- Publication number
- JPH0250086B2 JPH0250086B2 JP61316048A JP31604886A JPH0250086B2 JP H0250086 B2 JPH0250086 B2 JP H0250086B2 JP 61316048 A JP61316048 A JP 61316048A JP 31604886 A JP31604886 A JP 31604886A JP H0250086 B2 JPH0250086 B2 JP H0250086B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- quinolone
- compositions
- administration
- active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003826 tablet Substances 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 10
- -1 quinolone compound Chemical class 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 3
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims 4
- 239000002220 antihypertensive agent Substances 0.000 claims 4
- UZWAHQKAIZUPJV-UHFFFAOYSA-N 1-methyl-3-methylsulfinylquinolin-4-one Chemical compound C1=CC=C2N(C)C=C(S(C)=O)C(=O)C2=C1 UZWAHQKAIZUPJV-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 230000036772 blood pressure Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000019759 Maize starch Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/24—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in positions 2 and 4
- C07D265/26—Two oxygen atoms, e.g. isatoic anhydride
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7910558 | 1979-03-27 | ||
| GB7910558 | 1979-03-27 | ||
| GB7939505 | 1979-11-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62215526A JPS62215526A (ja) | 1987-09-22 |
| JPH0250086B2 true JPH0250086B2 (sv) | 1990-11-01 |
Family
ID=10504143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3961080A Granted JPS55130960A (en) | 1979-03-27 | 1980-03-27 | Quinolone compound |
| JP61316048A Granted JPS62215526A (ja) | 1979-03-27 | 1986-12-24 | 降圧剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3961080A Granted JPS55130960A (en) | 1979-03-27 | 1980-03-27 | Quinolone compound |
Country Status (10)
| Country | Link |
|---|---|
| JP (2) | JPS55130960A (sv) |
| BE (1) | BE882443A (sv) |
| CY (1) | CY1343A (sv) |
| ES (1) | ES489929A0 (sv) |
| GB (1) | GB2047691B (sv) |
| GE (1) | GEP19970835B (sv) |
| JO (1) | JO1072B1 (sv) |
| MX (1) | MX5950A (sv) |
| SU (1) | SU1124886A3 (sv) |
| ZA (1) | ZA801575B (sv) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA801575B (en) * | 1979-03-27 | 1981-03-25 | Boots Co Ltd | Therapeutic agents |
| IE51542B1 (en) * | 1980-09-26 | 1987-01-07 | Boots Co Ltd | Therapeutic agents |
| DE68917024D1 (de) * | 1988-05-24 | 1994-09-01 | Kirin Brewery | 4(1H)-Chinolonderivate. |
| US8697674B2 (en) | 2004-12-29 | 2014-04-15 | Naturon, Inc. | Xanthurenic acid derivative pharmaceutical compositions and methods related thereto |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55130960A (en) * | 1979-03-27 | 1980-10-11 | Boots Co Ltd | Quinolone compound |
-
1980
- 1980-03-18 ZA ZA00801575A patent/ZA801575B/xx unknown
- 1980-03-25 GB GB8010075A patent/GB2047691B/en not_active Expired
- 1980-03-25 CY CY1343A patent/CY1343A/xx unknown
- 1980-03-26 BE BE0/199956A patent/BE882443A/fr not_active IP Right Cessation
- 1980-03-26 ES ES489929A patent/ES489929A0/es active Granted
- 1980-03-26 JO JO19801072A patent/JO1072B1/en active
- 1980-03-27 JP JP3961080A patent/JPS55130960A/ja active Granted
-
1981
- 1981-01-19 SU SU802897803A patent/SU1124886A3/ru active
-
1985
- 1985-01-09 MX MX595085A patent/MX5950A/es unknown
-
1986
- 1986-12-24 JP JP61316048A patent/JPS62215526A/ja active Granted
-
1994
- 1994-09-07 GE GEAP19942162A patent/GEP19970835B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55130960A (en) * | 1979-03-27 | 1980-10-11 | Boots Co Ltd | Quinolone compound |
Also Published As
| Publication number | Publication date |
|---|---|
| GEP19970835B (en) | 1997-02-10 |
| GB2047691B (en) | 1983-07-20 |
| ZA801575B (en) | 1981-03-25 |
| ES8104232A1 (es) | 1981-04-16 |
| GB2047691A (en) | 1980-12-03 |
| BE882443A (fr) | 1980-09-26 |
| JPS62215526A (ja) | 1987-09-22 |
| JPS55130960A (en) | 1980-10-11 |
| JPH0114224B2 (sv) | 1989-03-10 |
| SU1124886A3 (ru) | 1984-11-15 |
| CY1343A (en) | 1987-01-16 |
| ES489929A0 (es) | 1981-04-16 |
| MX5950A (es) | 1993-11-01 |
| JO1072B1 (en) | 1982-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR2468367A1 (fr) | Compositions therapeutiques a base de quinolones | |
| CA2056967A1 (en) | Use of organic compounds | |
| SE461219B (sv) | 1,5-bensotiazepiner med kardiovaskulaer anvaendbarhet, foerfarande foer framstaellning daerav samt farmaceutiska kompositioner som innehaaller dem | |
| JPH0250086B2 (sv) | ||
| CA1117867A (en) | Pharmaceutical compositions containing tetrahydrotriazine diones | |
| JP2665357B2 (ja) | 心不全治療用医薬組成物 | |
| JPS6054316A (ja) | 虚血性心臓疾患治療剤 | |
| JPS5836960B2 (ja) | １−β−Ｄ−リボフラノシル−１．２．４−トリアゾ−ル−３−カルボキシアミドの製法 | |
| US4131678A (en) | Urapidil/furosemide compounds, compositions and use | |
| JP2710633B2 (ja) | 心臓疾患治療剤 | |
| JP3762799B2 (ja) | 抗不整脈剤及びその製法 | |
| JPS60158149A (ja) | 炎症抑制作用を有する１，４‐ナフトキノン誘導体 | |
| US4421755A (en) | Method of treating coronary heart disease with imidazo(4,5-B)pyridines | |
| CA1171789A (en) | Therapeutic agents | |
| JP3054743B2 (ja) | 移植組織の拒絶反応抑制剤 | |
| CS200242B2 (en) | Process for preparing inclusion complexes of derivatives prostacycline with beta-cyclodextrine | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| JPH024577B2 (sv) | ||
| US3459854A (en) | Tetracycline cyclohexyl sulphamate and process for preparation | |
| US2799617A (en) | Piperazine adipate compositions and treatment of helminth infections therewith | |
| EP0254068B1 (en) | Novel therapeutic agent for gastritis | |
| JPS5942318A (ja) | 製薬組成物、その製造法及び応用 | |
| JPS6056974A (ja) | 環式ジチオジアセトアミドおよびその製造方法並びに薬剤 | |
| US3773958A (en) | Methods of producing anti-arthritic activity using 3-substituted-thio-2,4-thiazolidinedione | |
| US3749781A (en) | Pharmaceutical composition and method of treatment |